Allozyne: Difference between revisions
No edit summary |
No edit summary |
||
| Line 32: | Line 32: | ||
}} |
}} |
||
{{Userspace draft|source=ArticleWizard|date=July 2010}} |
{{Userspace draft|source=ArticleWizard|date=July 2010}} |
||
'''ALLOZYNE''' is a clinical stage [[biotechnology]] company headquartered in [[Seattle]]’s biotech and high tech innovation corridor. Its lead product AZ01 is a long acting [[interferon beta]] for the treatment of the relapsing remitting form of [[multiple sclerosis]] |
'''ALLOZYNE''' is a clinical stage [[biotechnology]] company headquartered in [[Seattle]]’s biotech and high tech innovation corridor. Its lead product AZ01 is a long acting [[interferon beta]] for the treatment of the relapsing remitting form of [[multiple sclerosis]], a chronic degenerative disease characterized by [[demyelination]] of nerve fibers leading to severe nerve damage and increasing disability. Multiple sclerosis is estimated to affect 400,000 individuals in the US alone and 2.5 million worldwide<ref>{{cite journal |author= lich RF, Buschbacher RM, Cox MJ, Long WB, Winters KL, Becker DG. |title= Strategies to reduce hyperthermia in ambulatory multiple sclerosis patients |journal= J Long Term Eff Med Implants |volume=(14)6 |pages=467-479 |year=2004 | pmid= 15698375}}</ref>. AZ01 is currently undergoing Phase I clinical trials in the US. Preclinical data indicates that AZ01 has the potential to be dosed once monthly compared to the current standard of care dosed anywhere from once daily to once per week [reference here]. |
||
==Platform & Therapeutic Focus== |
==Platform & Therapeutic Focus== |
||
Revision as of 22:36, 21 July 2010
 | |
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | $36.4 million |
| Defunct | 2014  |
| Headquarters | , |
Number of employees | 25 |
| Website | http://www.allozyne.com |
ALLOZYNE is a clinical stage biotechnology company headquartered in Seattle’s biotech and high tech innovation corridor. Its lead product AZ01 is a long acting interferon beta for the treatment of the relapsing remitting form of multiple sclerosis, a chronic degenerative disease characterized by demyelination of nerve fibers leading to severe nerve damage and increasing disability. Multiple sclerosis is estimated to affect 400,000 individuals in the US alone and 2.5 million worldwide[1]. AZ01 is currently undergoing Phase I clinical trials in the US. Preclinical data indicates that AZ01 has the potential to be dosed once monthly compared to the current standard of care dosed anywhere from once daily to once per week [reference here].
Platform & Therapeutic Focus
ALLOZYNE has a therapeutic focus on chronic central nervous system and autoimmune diseases such as multiple sclerosis and Crohn’s disease. Their two platforms, Caesar and Vigenère, enable the creation of novel therapeutics that address unmet medical need associated with these diseases.
The names of the two platforms were inspired by the two encryption techniques used prior to and during <World War II> known as the <Caesar cipher> and <Vigenère cipher>. These platforms, like historical ciphering technologies, involve changes to the way messages are interpreted. These changes include modifications to the cellular machinery of both <E. coli> and mammalian cells so that the information encrypted in their <DNA> can introduce a variety of protein building blocks beyond the 20 that are found in all proteins throughout nature. This process of biological encryption has come to be known as “biociphering”. Additional available building blocks enable the creation more advanced protein therapeutics. The ability to customize the intrinsic properties and location of the 21st amino acid, allows for a variety of bioconjugation chemistries to be directed to any specific location within the protein. These biociphering platforms have opened the door to new protein therapeutic configurations including antibody-toxin, antibody-antibody, long acting as well as others. Application of these platforms to the development of protein based therapeutics enable therapeutics that address areas of unmet medical need. The first application of this technology was used to incorporate a variety of methionine analogs into human recombinant interferon beta [2]. One azide containing methionine analog was selected for its compatibility with a <bioconjugation> chemistry developed by Nobel Laureate, K. Barry Sharpless of The Scripps Research Institute, known as “<Click chemistry>”. This chemistry enabled the engineering of a long acting form of human interferon beta by conjugation to a half life extending moiety known as <polyethylene glycol> (PEG). Results were presented at the 2007 national ACS meeting[3]. On July 15th, 2010, ALLOZYNE announced the signing of an exclusive license agreement with The Scripps Research Institute for Click chemistry.[4]
References
- ^ lich RF, Buschbacher RM, Cox MJ, Long WB, Winters KL, Becker DG. (2004). "Strategies to reduce hyperthermia in ambulatory multiple sclerosis patients". J Long Term Eff Med Implants. (14)6: 467–479. PMID 15698375.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Wang A, Nairn NW, Johnson RS, Tirrell DA, Grabstein K. (2008). "Processing of N-terminal unnatural amino acids in recombinant human interferon-beta in Escherichia coli". Chembiochem. 9: 324–330. PMID 18098265.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - ^ "Site-specific PEGylation of interferon–beta by Cu(I)–catalyzed cycloaddition" (PDF).
- ^ "ALLOZYNE Fortifies Its Proprietary Position with a License for Click Chemistry, a Bioconjugation Enabling Cycloaddition Technology from The Scripps Research Institute" (Press release). BusinessWire. 15 July 2010. Retrieved 21 July 2010.